Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 7 de 7
Filtrer
1.
J Immigr Minor Health ; 21(6): 1200-1207, 2019 Dec.
Article de Anglais | MEDLINE | ID: mdl-30771144

RÉSUMÉ

Cross-border infectious disease transmission is a concern related to drug tourism from the U.S. to Mexico. We assessed this risk among people who inject drugs (PWID) in Tijuana, Mexico. We measured the prevalence and identified correlates of injecting with PWID visiting from the U.S. among PWID in Tijuana using univariable and multivariable logistic regression. Of 727 participants, 18.5% injected during the past 6 months in Mexico with U.S. PWID described mostly as friends (63%) or acquaintances (26%). Injecting with U.S. PWID was independently associated with higher education [adjusted odds ratio (aOR) = 1.13/year], deportation from the U.S. (aOR = 1.70), younger age at first injection (aOR = 0.96/year), more lifetime overdoses (aOR = 1.08), and, in the past 6 months, backloading (aOR = 4.00), syringe confiscation by the police (aOR = 3.02) and paying for sex (aOR = 2.98; all p-values < 0.05). Nearly one-fifth of PWID in Tijuana recently injected with U.S. PWID, and their reported risk behaviors could facilitate cross-border disease transmission.


Sujet(s)
Toxicomanie intraveineuse/épidémiologie , Adolescent , Adulte , Facteurs âges , Femelle , Humains , Mâle , Mexique/épidémiologie , Adulte d'âge moyen , Partage de seringue/statistiques et données numériques , Prévalence , Facteurs de risque , Facteurs sexuels , Facteurs socioéconomiques , États-Unis/ethnologie , Jeune adulte
2.
Drug Alcohol Depend ; 182: 67-73, 2018 01 01.
Article de Anglais | MEDLINE | ID: mdl-29169035

RÉSUMÉ

BACKGROUND: The prevention of drug injecting is often cited as a justification for the deployment of law enforcement and for the continuation of drug criminalization policies. We sought to characterize the impact of law enforcement interactions on the risk that people who inject drugs (PWID) report assisting others with injection initiation in three North American countries. METHODS: Cross-sectional data from PWID participating in cohort studies in three cities (San Diego, USA; Tijuana, Mexico; Vancouver, Canada) were pooled (August 2014-December 2016). The dependent variable was defined as recently (i.e., past six months) providing injection initiation assistance; the primary independent variable was the frequency of recent law enforcement interactions, defined categorically (0 vs. 1 vs. 2-5 vs. ≥6). We employed multivariable logistic regression analyses to assess this relationship while controlling for potential confounders. RESULTS: Among 2122 participants, 87 (4.1%) reported recently providing injection initiation assistance, and 802 (37.8%) reported recent law enforcement interactions. Reporting either one or more than five recent interactions with law enforcement was not significantly associated with injection initiation assistance. Reporting 2-5 law enforcement interactions was associated with initiation assistance (Adjusted Odds Ratio=1.74, 95% Confidence Interval: 1.01-3.02). CONCLUSIONS: Reporting interactions with law enforcement was not associated with a reduced likelihood that PWID reported initiating others into injection drug use. Instead, we identified a positive association between reporting law enforcement interactions and injection initiation assistance among PWID in multiple settings. These findings raise concerns regarding the effectiveness of drug law enforcement to deter injection drug use initiation.


Sujet(s)
Application de la loi/méthodes , Toxicomanie intraveineuse/épidémiologie , Toxicomanie intraveineuse/prévention et contrôle , Adulte , Colombie-Britannique/épidémiologie , Californie/épidémiologie , Cognition , Études de cohortes , Études transversales , Femelle , Humains , Mâle , Mexique/épidémiologie , Adulte d'âge moyen , Amérique du Nord/épidémiologie , Études prospectives , Toxicomanie intraveineuse/diagnostic
3.
Int J Tuberc Lung Dis ; 19(9): 1057-64, 2015 Sep.
Article de Anglais | MEDLINE | ID: mdl-26260824

RÉSUMÉ

BACKGROUND: Although directly observed therapy (DOT) is recommended worldwide for monitoring anti-tuberculosis treatment, transportation and personnel requirements limit its use. OBJECTIVE: To evaluate the feasibility and acceptability of 'video DOT' (VDOT), which allows patients to record and transmit medication ingestion via videos watched remotely by health care providers to document adherence. METHODS: We conducted a single-arm trial among tuberculosis (TB) patients in San Diego, California, USA, (n = 43) and Tijuana, Mexico (n = 9) to represent high- and low-resource settings. Pre-/post-treatment interviews assessed participant characteristics and experiences. Adherence was defined as the proportion of observed doses to expected doses. RESULTS: The mean age was 37 years (range 18-86), 50% were male, and 88% were non-Caucasian. The mean duration of VDOT use was 5.5 months (range 1-11). Adherence was similar in San Diego (93%) and Tijuana (96%). Compared to time on in-person DOT, 92% preferred VDOT, 81% thought VDOT was more confidential, 89% never/rarely had problems recording videos, and 100% would recommend VDOT to others. Seven (13%) participants were returned to in-person DOT and six (12%) additional participants had their phones lost, broken or stolen. CONCLUSIONS: VDOT was feasible and acceptable, with high adherence in both high- and low-resource settings. Efficacy and cost-effectiveness studies are needed.


Sujet(s)
Antituberculeux/usage thérapeutique , Thérapie sous observation directe/méthodes , Adhésion au traitement médicamenteux , Télémédecine/méthodes , Tuberculose/traitement médicamenteux , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Californie , Téléphones portables , Analyse coût-bénéfice , Études de faisabilité , Femelle , Humains , Mâle , Mexique , Adulte d'âge moyen , Projets pilotes , Enregistrement sur magnétoscope , Jeune adulte
4.
Int J Tuberc Lung Dis ; 18(2): 227-32, 2014 Feb.
Article de Anglais | MEDLINE | ID: mdl-24429318

RÉSUMÉ

OBJECTIVE: To establish breakpoint concentrations for the fluoroquinolones (moxifloxacin [MFX] and ofloxacin [OFX]) and injectable second-line drugs (amikacin [AMK], kanamycin [KM] and capreomycin [CPM]) using the microscopic observation drug susceptibility (MODS) assay. SETTING: A multinational study conducted between February 2011 and August 2012 in Peru, India, Moldova and South Africa. DESIGN: In the first phase, breakpoints for the fluoroquinolones and injectable second-line drugs (n = 58) were determined. In the second phase, MODS second-line drug susceptibility testing (DST) as an indirect test was compared to MGIT™ DST (n = 89). In the third (n = 30) and fourth (n = 156) phases, we determined the reproducibility and concordance of MODS second-line DST directly from sputum. RESULTS: Breakpoints for MFX (0.5 µg/ml), OFX (1 µg/ml), AMK (2 µg/ml), KM (5 µg/ml) and CPM (2.5 µg/ml) were determined. In all phases, MODS results were highly concordant with MGIT DST. The few discrepancies suggest that the MODS breakpoint concentrations for some drugs may be too low. CONCLUSION: MODS second-line DST yielded comparable results to MGIT second-line DST, and is thus a promising alternative. Further studies are needed to confirm the accuracy of the drug breakpoints and the reliability of MODS second-line DST as a direct test.


Sujet(s)
Antituberculeux/usage thérapeutique , Multirésistance bactérienne aux médicaments , Tests de sensibilité microbienne/méthodes , Microscopie , Mycobacterium tuberculosis/effets des médicaments et des substances chimiques , Tuberculose multirésistante/diagnostic , Tuberculose multirésistante/traitement médicamenteux , Tuberculose pulmonaire/diagnostic , Tuberculose pulmonaire/traitement médicamenteux , Amikacine/usage thérapeutique , Capréomycine/usage thérapeutique , Fluoroquinolones/usage thérapeutique , Humains , Inde , Kanamycine/usage thérapeutique , Moldavie , Moxifloxacine , Mycobacterium tuberculosis/isolement et purification , Ofloxacine/usage thérapeutique , Pérou , Valeur prédictive des tests , Reproductibilité des résultats , République d'Afrique du Sud , Expectoration/microbiologie , Tuberculose multirésistante/microbiologie , Tuberculose pulmonaire/microbiologie
5.
Int J Tuberc Lung Dis ; 17(11): 1452-8, 2013 Nov.
Article de Anglais | MEDLINE | ID: mdl-24125450

RÉSUMÉ

SETTING: Tijuana, Mexico. OBJECTIVE: To describe the association between salivary cotinine levels and interferon-gamma (IFN-γ) release assay results. DESIGN: We conducted a cross-sectional study among injection drug users. Salivary cotinine levels were measured using NicAlert, a semi-quantitative dipstick assay. QuantiFERON©-TB Gold In-Tube (QFT-GIT) was used to determine Mycobacterium tuberculosis infection. RESULTS: Among 234 participants, the prevalence of QFT-GIT positivity for NicAlert cotinine categories 0 (non-smoking), 1 (second-hand smoke exposure or low-level smoking) and 26 (regular smoking) were respectively 42.1%, 46.4% and 65.2% (Ptrend 0.012). We found increasing trends in QFT-GIT positivity (Ptrend 0.003) and IFN-γ concentrations (Spearman's r 0.200, P 0.002) across cotinine levels 0 to 6. In multivariable log-binomial regression models adjusted for education, cotinine levels were not associated with QFT-GIT positivity when included as smoking categories (1 and 26 vs. 0), but were independently associated with QFT-GIT positivity when included as an ordinal variable (prevalence ratio 1.09 per 1 cotinine level, 95%CI 1.021.16). CONCLUSION: Our findings suggest that a dose-response relationship exists between tobacco smoke exposure and M. tuberculosis infection. Longitudinal studies that use biochemical measures for smoking status are needed to confirm our findings.


Sujet(s)
Cotinine/métabolisme , Mycobacterium tuberculosis/isolement et purification , Salive/métabolisme , Fumer/métabolisme , Tuberculose/microbiologie , Adulte , Loi du khi-deux , Études transversales , Relation dose-effet des médicaments , Usagers de drogues , Femelle , Humains , Tests de libération d'interféron-gamma , Mâle , Mexique/épidémiologie , Adulte d'âge moyen , Analyse multifactorielle , Valeur prédictive des tests , Prévalence , Bandelettes réactives , Facteurs de risque , Fumer/effets indésirables , Fumer/épidémiologie , Toxicomanie intraveineuse/épidémiologie , Tuberculose/diagnostic , Tuberculose/épidémiologie
6.
Int J Tuberc Lung Dis ; 13(8): 962-8, 2009 Aug.
Article de Anglais | MEDLINE | ID: mdl-19723375

RÉSUMÉ

OBJECTIVE: To assess the cost-effectiveness of screening for latent tuberculosis infection (LTBI) using a commercially available detection test and treating individuals at high risk for human immunodeficiency virus (HIV) infection in a middle-income country. DESIGN: We developed a Markov model to evaluate the cost per LTBI case detected, TB case averted and quality-adjusted life year (QALY) gained for a cohort of 1000 individuals at high risk for HIV infection over 20 years. Baseline model inputs for LTBI prevalence were obtained from published literature and cross-sectional data from tuberculosis (TB) screening using QuantiFERON-TB Gold In-Tube (QFT-GIT) testing among sex workers and illicit drug users at high risk for HIV recruited through street outreach in Tijuana, Mexico. Costs are reported in 2007 US dollars. Future costs and QALYs were discounted at 3% per year. Sensitivity analyses were performed to evaluate model robustness. RESULTS: Over 20 years, we estimate the program would prevent 78 cases of active TB and 55 TB-related deaths. The incremental cost per case of LTBI detected was US$730, cost per active TB averted was US$529 and cost per QALY gained was US$108. CONCLUSIONS: In settings of endemic TB and escalating HIV incidence, targeting LTBI screening and treatment among high-risk groups may be highly cost-effective.


Sujet(s)
Dépistage de masse/économie , Tuberculose/diagnostic , Tuberculose/thérapie , Comorbidité , Analyse coût-bénéfice , Infections à VIH/épidémiologie , Humains , Chaines de Markov , Mexique/épidémiologie , Méthode de Monte Carlo , Années de vie ajustées sur la qualité , Tuberculose/économie , Tuberculose/épidémiologie
7.
Int J Tuberc Lung Dis ; 13(5): 626-32, 2009 May.
Article de Anglais | MEDLINE | ID: mdl-19383197

RÉSUMÉ

BACKGROUND: We studied prevalence and correlates of latent tuberculosis infection (LTBI) among injection drug users (IDUs) in Tijuana, Mexico, where tuberculosis (TB) is endemic. METHODS: IDUs aged > or =18 years were recruited via respondent-driven sampling (RDS) and underwent standardized interviews, human immunodeficiency virus (HIV) antibody testing and LTBI screening using Quanti-FERON((R))-TB Gold In-Tube, a whole-blood interferon-gamma release assay (IGRA). LTBI prevalence was estimated and correlates were identified using RDS-weighted logistic regression. RESULTS: Of 1020 IDUs, 681 (67%) tested IGRA-positive and 44 (4%) tested HIV-positive. Mean age was 37 years, 88% were male and 98% were Mexican-born. IGRA positivity was associated with recruitment nearest the US border (aOR 1.64, 95%CI 1.09-2.48), increasing years of injection (aOR 1.20/5 years, 95%CI 1.07-1.34), and years lived in Tijuana (aOR 1.10/5 years, 95%CI 1.03-1.18). Speaking some English (aOR 0.38, 95%CI 0.25-0.57) and injecting most often at home in the past 6 months (aOR 0.68, 95%CI 0.45-0.99) were inversely associated with IGRA positivity. DISCUSSION: Increased LTBI prevalence among IDUs in Tijuana appears to be associated with greater drug involvement. Given the high risk for HIV infection among Tijuana's IDUs, interventions are urgently needed to prevent HIV infection and treat LTBI among IDUs before these epidemics collide.


Sujet(s)
Toxicomanie intraveineuse/complications , Tuberculose/épidémiologie , Adulte , Marqueurs biologiques/sang , Femelle , Études de suivi , Humains , Interféron gamma/sang , Mâle , Mexique/épidémiologie , Prévalence , Pronostic , Études rétrospectives , Facteurs de risque , Toxicomanie intraveineuse/sang , Toxicomanie intraveineuse/épidémiologie , Tuberculose/sang , Tuberculose/complications
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE